These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 30488824)

  • 1. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
    Koppolu V; Rekha Vasigala VK
    J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Option Value of Innovative Treatments for Metastatic Melanoma.
    Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
    Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
    Carreau NA; Pavlick AC
    Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
    Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
    JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report.
    Lepir T; Zaghouani M; Roche SP; Li YY; Suarez M; Irias MJ; Savaraj N
    Medicine (Baltimore); 2019 Jan; 98(2):e13804. PubMed ID: 30633154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.
    De Luca R; Meraviglia S; Blasi L; Maiorana A; Cicero G
    Curr Oncol; 2020 Apr; 27(2):e75-e80. PubMed ID: 32489255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
    Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
    PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma During Immunotherapy Era.
    Sari M; Saip P
    J Coll Physicians Surg Pak; 2018 Nov; 28(11):891-892. PubMed ID: 30369388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in melanoma: latest evidence and clinical potential.
    Johnson DB; Peng C; Sosman JA
    Ther Adv Med Oncol; 2015 Mar; 7(2):97-106. PubMed ID: 25755682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
    Kamimura N; Wolf AM; Iwai Y
    J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Nonmelanoma Skin Cancer.
    Bassas Freixas P; Aparicio Español G; García-Patos Briones V
    Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):353-359. PubMed ID: 30837075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.